Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Muus

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Leukemia|February 24, 2012
Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVONS Daenen, B van der Holt, A W Dekker, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Leukemia|February 24, 2012
Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVONS Daenen, B van der Holt, A W Dekker, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 7